Summary :
PE firm Carlyle-backed SeQuent Scientific has acquired 100% stake in Brazil-based Nourrie Sade e Nutrio Animal Ltd for $5mn (Rs36.2cr), via its wholly-owned subsidiary Alivira Animal Health. The acquisition provides Alivira complete control over the value-chain of Transuin, a Ractopamine based swine product currently manufactured at Nourrie, which is at present the third largest product in Alivira Brazils portfolio.
PE firm Carlyle-backed SeQuent Scientific has acquired 100% stake in Brazil-based Nourrie Saúde e Nutrição Animal Ltd for $5 million (Rs 36.2 crore), through its wholly-owned subsidiary Alivira Animal Health.
On December 16, SeQuent introduced it had inked a definitive pact for the acquisition, as part of the platform’s superior technique to spice up Alivira’s footprint in Brazil’s pet market.
Brazil has the world’s fourth largest pet market with an estimated market dimension of BRL 1.8 billion, rising yearly at 16%.
The addition of Nourrie’s enterprise has almost doubled the product portfolio out there to Alivira for commercialization in Brazil, with additions in each the nutraceutical and therapeutic product classes. Nourrie additionally brings a robust pipeline of 20 merchandise underneath improvement, 12 of that are deliberate for launch within the subsequent fiscal.
The acquisition gives Alivira full management over the value-chain of Transuin, a Ractopamine primarily based swine product presently manufactured at Nourrie, which is at current the third largest product in Alivira Brazil’s portfolio.
With entry to Alivira’s personal API manufactured within the USFDA accepted plant in Visakhapatnam, India and extension of product vary with upcoming registration approvals, Alivira intends to fast-track development for Transuin franchise in each Brazil and different Latam markets, the corporate stated in an announcement.
The growth of the swine and poultry section will likely be additional catalysed with almost 5 new product launches anticipated within the close to time period.
Consequent to the oversight of Alivira administration, Nourrie’s pet enterprise outlook has been promising, with month-to-month revenues having grown by over 50% in February 2022, in comparison with these on the time of acquisition announcement in December 2021.
Alivira already has a longtime track-record of efficiency in Brazil, with the native operations rising 5-fold at a CAGR of 57% over the past 5 years. Brazil has emerged because the third largest market for Alivira, subsequent solely to Spain and Turkey.
